financetom
Business
financetom
/
Business
/
Canadian oil and gas CEOs take cautious approach during price rout
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canadian oil and gas CEOs take cautious approach during price rout
Apr 8, 2025 2:35 PM

*

Global oil prices at four-year lows after tariff-related

selloff

*

Canadian oil production growth this year could be limited

if

lower prices persist, economists say

*

Canadian companies holding off on making changes for now

(Adds comments from Cenovus, Tourmaline, investor)

By Amanda Stephenson

TORONTO, April 8 (Reuters) - CEOs of Canadian oil and

gas producers said on Tuesday they are seeking to avoid making

abrupt decisions about spending or production, as global oil

prices hit four-year lows and recession fears grow.

Canada, the world's No. 4 oil exporter, was spared the Trump

administration's broad global tariffs on April 2 but faces U.S.

tariffs on steel and cars.

"My suspicion is that most companies will work to invest

through this cycle, though I would also say that in price

downturns, this industry does a really good job of shedding

costs," said Jon McKenzie, CEO of oil sands producer Cenovus

Energy ( CVE ), in an interview in Toronto. "We'll probably see

some cost reductions throughout the industry."

Doug Bartole, CEO of InPlay Oil ( IPOOF ), said his company

does not foresee reducing production or capital spending in the

short term.

"Don't make any rash decisions. Let's take a longer view of

things and see where it all settles out," Bartole said.

But he said that could change if oil continues its slide.

"I think $50 oil would change things a bit more, obviously,"

Bartole said. "We can easily pull back capital. We're a small

company, we're nimble. We make decisions quick."

On Tuesday, ATB Capital Markets lowered its price target for

InPlay shares, citing "the current WTI pricing environment."

Brent futures and West Texas Intermediate crude futures have

slumped since U.S. President Donald Trump's April 2 announcement

of broad tariffs.

Oil prices fell further on Tuesday, trading around $60 per

barrel, over recession fears exacerbated by trade conflict

between the United States and China.

ATB said in a research note it still expects Canadian

production to grow this year, but warned sustained lower oil

prices would pressure companies to limit spending and constrain

output growth.

"If we do go into a recession and prices are a bit lower,

then it could ultimately affect our capital plans," said Mike

Rose, CEO of Tourmaline Oil ( TRMLF ), in an interview.

Peter Tertzakian, economist and founder of think tank

Studio.Energy, said Canada's biggest oil sands companies can be

profitable at lower prices, but smaller, higher-cost operators

may revise their capital budgets if prices do not rebound.

"It's a question of whether there's enough (money) to grow,

and if $61-$62 is sustained for the balance of the year, we're

not likely to grow very much," Tertzakian said.

Eric Nuttall, senior portfolio manager with Ninepoint

Partners, does not expect much loss of Canadian production this

year.

But he added he would not be surprised to see job losses,

especially in the drilling sector and among smaller producers.

"Companies are going to be proactive, they're not going to

sit around and wait," he said. "Where there's discretionary

expenditures to be cut, you're going to be seeing that in real

time."

Chris Carlsen, CEO of Canadian natural gas producer

Birchcliff Energy ( BIREF ), said the slide in oil prices could

benefit natural gas producers in the long term if it leads to an

overall reduction in North American drilling.

"When they're drilling less oil, there's less associated gas

with that, which means we could be short on the natural gas

production side," Carlsen said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Price: 5.73, Change: -0.05, Percent Change: -0.87 ...
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) on Friday reported a narrower loss for the first quarter even though the company has not generated revenues from operations and had an accumulated deficit of $45.2 million at the end of March. The company reported a first-quarter net loss of $2.4 million, or $0.03 per share, compared...
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Friday their marketing authorization applications for HLX14, a denosumab biosimilar, have been validated by the European Medicines Agency. The submissions were based on a phase 3 study comparing HLX14 with denosumab in postmenopausal women with osteoporosis, the companies said. Henlius licensed HLX14 to Organon in 2022...
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) late Thursday reported that an ongoing phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%. Of 26 patients in all the trial cohorts who have had their first scan while...
Copyright 2023-2025 - www.financetom.com All Rights Reserved